Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Yidao Biotechnology

Request full access

Yidao Biotechnology research and develops vaccines and biomedical products

Suzhou Shi, ChinaFounded 2017Biotech & Life Sciences

About Yidao Biotechnology

Yidao Biotechnology (Suzhou) Co., Ltd. is a clinical-stage biopharmaceutical company established in March 2017, focusing on the development and industrialization of innovative human vaccines. The company was founded by a team described as national specially-invited experts and seasoned professionals from the global vaccine and pharmaceutical industries, led by Chairman Shi Li and General Manager Zhi Zhang. The management team brings an average of over 20 years of professional experience, having navigated the vaccine industry's evolution from early growth to periods of rapid technological advancement.

Initially founded in Shanghai's Zhangjiang Pharma Valley, the company signed a strategic cooperation agreement in December 2019 to relocate its headquarters to Suzhou, where it broke ground on a large-scale vaccine industrialization base in 2021. The firm's business model centers on creating and advancing a proprietary pipeline of vaccine candidates to address significant unmet medical needs in infectious diseases and oncology. Its revenue generation will depend on the successful clinical development, regulatory approval, and commercialization of these products.

Yidao's pipeline is spearheaded by two advanced assets: a recombinant zoster (shingles) vaccine using CHO cells, which is in Phase III clinical trials, and a 9-valent recombinant Human Papillomavirus (HPV) vaccine, currently in Phase II trials. The company achieved a significant milestone in July 2020 when it received clinical trial approval for both candidates, with the shingles vaccine being the first of its kind developed by a domestic Chinese company to reach this stage. Its earlier-stage pipeline includes a vaccine for respiratory syncytial virus (RSV) at the IND approval phase, alongside therapeutic vaccines for stomach cancer and COVID-19 in the discovery phase. The company's development is supported by a formidable roster of domestic and international investment funds, including Lilly Asia Ventures, Northern Light Venture Capital, Qiming Venture Partners, OrbiMed, and Sequoia China, secured through multiple financing rounds since 2018.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Suzhou Shi, China
Open positions
5
Dealroom signal
20.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing May 2024 $25M $100M Qiming Venture Partners —
SERIES COther financing May 2021 $55M $220M Qiming Venture Partners —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Yidao Biotechnology website traffic

Latest recorded traffic for Yidao Biotechnology is 40 monthly website visits, down 81.8% over the last three months.

Latest monthly visits40 3-month web change-81.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Yidao Biotechnology in the Suzhou Shi ecosystem

Live from Dealroom

The Yidao Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • NLVC

Series B and later1 investor entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Yidao Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Yidao Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.